C5 and COVID-19: Although eculizumab is the only approved treatment for humans that inhibits complement cascade at the moment (96), anti-C5aR1 monoclonal antibodies blocking this receptor are a promising and more specific treatment in severe COVID-19 patients due to the fact that C5a is a chemoattractant factor that facilitates the adherence of leukocytes to the endothelium (91).